Sunday Health and Re:Cognition Health Form Collaboration to Transform Cognitive Care and Delay DementiaBy: Sunday Health, Inc. and Re:Cognition Health ALEXANDRIA, Va. - March 10, 2025 - PRLog -- Sunday Health, Inc., a provider of personalized cognitive care, and Re:Cognition Health, a leader in clinical trials and FDA-approved treatments for Alzheimer's and related dementias, today announced a strategic collaboration to improve early diagnosis, treatment access, and long-term cognitive care for individuals experiencing mild cognitive impairment (MCI) and dementia. By working together, Re:Cognition Health and Sunday Health aim to close critical gaps in cognitive care and offer patients access to the latest clinical trials and new pharmacological treatments for MCI and Alzheimer's disease.
"At Sunday Health, we believe that early diagnosis and interventions, including addressing modifiable risk factors, are key to delaying or preventing dementia and extending personal agency for as long as possible," said Maria Thomas, Co-Founder and CEO of Sunday Health. "Working together with Re:Cognition Health, we can help patients quickly learn about and gain access to relevant clinical trials as well as the latest FDA-approved treatments (Leqembi and Kisunla) for MCI and early Alzheimer's." "Our collaboration with Sunday Health enhances our ability to deliver the latest advancements in cognitive care, strengthening the connection between early intervention, clinical trial access, and ongoing support.," said Dr. Emer MacSweeney, Founder and CEO of Re:Cognition Health. "Patients who are not eligible for clinical trials or the latest infusion therapies can still enroll in Sunday Health's comprehensive, personalized cognitive care model to get help managing their condition and retain independence as long as possible."
About Sunday Health: Sunday Health is pioneering a new model of cognitive care, designed to increase access, improve outcomes, and support both patients and healthcare providers. By focusing on mild cognitive impairment (MCI) and early-stage dementia, it provides proactive, evidence-based care before patients reach a crisis point. Sunday Health's approach prioritizes early intervention, prevention, and continuous monitoring to help patients maintain cognitive function and independence for longer. Sunday Health is accepting new patients in the DC-MD-VA region with little wait time. Medicare Part B and major commercial insurance are accepted, and patients can be seen via telehealth or in-person in the practice's Vienna, VA office. About Re:Cognition Health: Re:Cognition Health is a leading brain and mind clinic dedicated to advancing the diagnosis, treatment and care of individuals experiencing cognitive impairment. With nearly 15 years at the forefront of brain health in the UK, the organization expanded to the U.S. in 2018, establishing its first center in Fairfax, Virginia. Specializing in Phase 2 and 3 clinical trials for disease-modifying treatments targeting mild cognitive impairment (MCI) and Alzheimer's disease, Re:Cognition Health's U.S. centers are led by renowned neurologist Dr. Raymond Scott Turner. In addition to its six UK clinics, the company operates centers in Washington, D.C., Houston, Chicago, and Dallas-Fort Worth, providing access to international clinical trials for Alzheimer's and other neurological conditions. The multidisciplinary team takes a patient-centered approach, integrating cutting-edge research and evidence-based treatments to drive global progress in neurodegenerative disease therapies. End
|